Company Logo

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications are not effective for a lot of people who are depressed. Personalized treatment could be the answer.

Cue is an intervention platform that converts sensor data collected from smartphones into personalized micro-interventions for improving mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to identify their predictors of feature and reveal distinct features that are able to change mood as time passes.

Predictors of Mood

Depression is a leading cause of mental illness in the world.1 Yet only half of those affected receive treatment. In order to improve outcomes, healthcare professionals must be able to identify and treat patients who have the highest chance of responding to specific treatments.

Personalized depression treatment is one method to achieve this. By using mobile phone sensors and an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. Two grants worth more than $10 million will be used to discover the biological and behavioral factors that predict response.

The majority of research into predictors of depression treatment effectiveness has centered on the sociodemographic and clinical aspects. These include demographics such as age, gender, and education, as well as clinical aspects like severity of symptom and comorbidities as well as biological markers.

Very few studies have used longitudinal data to predict mood in individuals. Few studies also take into account the fact that moods can differ significantly between individuals. It is therefore important to develop methods which allow for the identification and quantification of personal differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can detect distinct patterns of behavior and emotions that vary between individuals.

The team also developed a machine-learning algorithm that can create dynamic predictors for the mood of each person's depression. The algorithm combines these individual variations into a distinct "digital phenotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated severity scale for symptom severity. The correlation was low however (Pearson r = 0,08; P-value adjusted for BH = 3.55 x 10 03) and varied widely between individuals.

Predictors of symptoms

Depression is the leading cause of disability around the world1, but it is often misdiagnosed and untreated2. Depression disorders are rarely treated due to the stigma associated with them and the absence of effective interventions.

To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying patterns that can predict symptoms is essential. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only identify a handful of characteristics that are associated with depression.

Machine learning can enhance the accuracy of diagnosis and treatment for private depression treatment by combining continuous, digital behavioral phenotypes gathered from smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes are able to capture a variety of distinct behaviors and activities that are difficult to capture through interviews, and also allow for continuous, high-resolution measurements.

The study comprised University of California Los Angeles students with moderate to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and depression treatment residential program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical treatment depending on their depression treatment in pregnancy severity. Patients who scored high on the CAT DI of 35 or 65 were assigned to online support via an online peer coach, whereas those with a score of 75 patients were referred to psychotherapy in-person.

Participants were asked a series questions at the beginning of the study about their demographics and psychosocial traits. The questions asked included education, age, sex and gender and marital status, financial status, whether they were divorced or not, current suicidal ideas, intent or attempts, and the frequency with which they consumed alcohol. Participants also rated their degree of depression can be treated symptom severity on a scale of 0-100 using the CAT-DI. The CAT-DI assessment was carried out every two weeks for those who received online support and weekly for those who received in-person support.

Predictors of the Reaction to Treatment

A customized treatment for depression is currently a research priority and a lot of studies are aimed to identify predictors that enable clinicians to determine the most effective drugs for each person. Pharmacogenetics in particular is a method of identifying genetic variations that affect how the body's metabolism reacts to drugs. This lets doctors choose the medications that are most likely to work for each patient, reducing the amount of time and effort required for trials and errors, while avoid any negative side consequences.

Another approach that is promising is to create prediction models that combine the clinical data with neural imaging data. These models can then be used to determine the most appropriate combination of variables predictors of a specific outcome, such as whether or not a drug will improve mood and symptoms. These models can be used to determine the response of a patient to a treatment they are currently receiving and help doctors maximize the effectiveness of their treatment currently being administered.

A new generation of machines employs machine learning methods such as the supervised and classification algorithms, regularized logistic regression and tree-based methods to combine the effects from multiple variables and improve predictive accuracy. These models have been shown to be useful in predicting the outcome of treatment for example, the response to antidepressants. These models are getting more popular in psychiatry, and it is likely that they will become the norm for future clinical practice.

Research into depression's underlying mechanisms continues, as well as predictive models based on ML. Recent findings suggest that depression is connected to the dysfunctions of specific neural networks. This theory suggests that the treatment for depression will be individualized based on targeted therapies that target these circuits in order to restore normal function.

Internet-based-based therapies can be a way to accomplish this. They can offer more customized and personalized experience for patients. For instance, one study discovered that a web-based treatment was more effective than standard treatment in alleviating symptoms and ensuring an improved quality of life for those suffering from MDD. In addition, a controlled randomized trial of a personalized approach to treating depression showed steady improvement and decreased side effects in a significant number of participants.

Predictors of Side Effects

In the treatment of depression, one of the most difficult aspects is predicting and identifying the antidepressant that will cause minimal or zero side effects. Many patients take a trial-and-error approach, with several medications prescribed until they find one that is effective and tolerable. Pharmacogenetics provides a novel and exciting way to select antidepressant drugs that are more efficient and targeted.

There are many predictors that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of patients such as ethnicity or gender, and the presence of comorbidities. To identify the most reliable and valid predictors of a specific treatment, random controlled trials with larger samples will be required. This is because the identifying of interactions or moderators may be much more difficult in trials that only focus on a single instance of treatment per participant instead of multiple sessions of treatment over time.

Furthermore the prediction of a patient's response to a specific medication is likely to require information on symptoms and comorbidities and the patient's personal experience with tolerability and efficacy. At present, only a handful of easily assessable sociodemographic variables and clinical variables seem to be consistently associated with response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

Many challenges remain in the application of pharmacogenetics to treat depression. First is a thorough understanding of the genetic mechanisms is needed, as is an understanding of what is a reliable indicator of treatment response. In addition, ethical concerns, such as privacy and the ethical use of personal genetic information must be carefully considered. In the long term, pharmacogenetics may offer a chance to lessen the stigma associated with mental health treatment and to improve the outcomes of those suffering with depression. But, like all approaches to psychiatry, careful consideration and implementation is required. For now, it is recommended to provide patients with an array of depression medications that work and encourage patients to openly talk with their doctors.